Back

Efficacy and safety of catheter ablation of VT using the QDOT Micro catheter: a propensity-matched dual-center comparison with the thermocool SmartTouch catheter

16 April 2023 (08:00 - 20:00)
Organised by:
Congress Presentation Part of: Ventricular Arrhythmias and SCD - Round 4 - Ablation Ablation of Ventricular Arrhythmias EHRA Premium Access EHRA 2023

About the speaker

Photo
Doctor Paolo Compagnucci

University Hospital Riuniti of Ancona, Ancona (Italy)

6 More presentations in this session

Presentation thumbnail
The effect of scar imaging quality on in-silico pace-mapping of post-infarction ventricular tachycardia
Doctor M. Bishop (London, GB)
Abstract Slides
Presentation thumbnail
Characteristics of recurrent ventricular tachycardias after stereotactic body radiotherapy
Associate Professor P. Peichl (Prague, CZ)
Abstract Slides
Presentation thumbnail
Ventricular tachycardia substrates in young patients with repaired tetralogy of fallot
Mr J. Wallet (Leiden, NL)
Abstract Slides
Presentation thumbnail
Catheter ablation as first line treatment in patients with ischemic cardiomyopathy, tolerated ventricular tachycardia and left ventricular ejection fraction over 35%: long term outcomes
Mr R. Rademaker (Leiden, NL)
Abstract Slides
Presentation thumbnail
Peak frequency mapping to differentiate near-field from far-field electrograms for ventricular tachycardia ablation: initial results
Doctor L. Guido Lopez (Buenos Aires, AR)
Abstract Slides

Access the full session

Session thumbnail
Ventricular Arrhythmias and SCD - Round 4 - Ablation

The Event

Event poster

EHRA 2023

16 April - 18 April 2023
You may be interested in
thumbnail
Congress Presentation
Case 2 - implantable cardioverter defibrillator, catheter ablation, or both for secondary prevention?
thumbnail
Congress Presentation
Case 1 - first choice treatment: antiarrhythmic drugs or catheter ablation?
thumbnail
Congress Presentation
Ablation is alternative to ICD therapy in post-myocardial infarction patients with haemodynamically well-tolerated sustained monomorphic VT and LVEF>40%: con

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources